Literature DB >> 31002815

CSTP1 inhibits IL-6 expression through targeting Akt/FoxO3a signaling pathway in bladder cancer cells.

Dexiang Zhuo1, Yongyang Wu1, Jia Luo1, Ling Deng2, Xiaohua Niu3.   

Abstract

CSTP1, a recently identified protein phosphotase, is frequently repressed in bladder cancers. Previous results showed that CSTP1 over-expression inhibited cell cycle progression and promoted apoptosis through dephosphorylating Akt kinase at Ser473 site in bladder cancer cells, but the mechanisms how CSTP1 exerted tumor suppressive activity remains unclear. In this study, we analyzed the gene expression profile changes that affected by CSTP1 overexpression by microarray, and reported that CSTP1 decreased IL-6 expression/secretion in bladder cancer cells and re-expression of IL-6 abrogated CSTP1's tumor suppressive activity. We also found that FoxO3a occupy IL-6 gene promoter and repressed IL mRNA transcription. Further results showed that decreased expression of IL-6 in CSTP1-overexpressing cells inactivated Stat3 transcriptional factor, which resulted in the down-regulation of cyclin D1, Bcl-xl expression. Spearman correlation analysis revealed that the mRNA level of CSTP1 correlated inversely with that of IL-6 in bladder cancer tissues. In conclusion, our studies revealed that protein phosphotase CSTP1 inhibited IL-6 expression through targeting Akt/FoxO3a signaling pathway and IL-6 inactivated Stat3 was necessary for CSTP1's tumor suppressive function.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Akt; Bladder cancer; CSTP1; FoxO3A; Interleukin-6; Stat3

Mesh:

Substances:

Year:  2019        PMID: 31002815     DOI: 10.1016/j.yexcr.2019.04.019

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  CPPED1-targeting microRNA-371a-5p expression in human placenta associates with spontaneous delivery.

Authors:  Ravindra Daddali; Marja Ojaniemi; Mikko Hallman; Mika Rämet; Antti M Haapalainen
Journal:  PLoS One       Date:  2020-06-10       Impact factor: 3.240

2.  Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer.

Authors:  Jianfeng Ma; Jinchun Qi; Shoubin Li; Chaohua Zhang; Haijiang Wang; Lijun Shao; Xiaofei Yuan; Quan Sha
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  FOXO3A Expression in Upper Tract Urothelial Carcinoma.

Authors:  Guoyao Zhang; Wanping Shi; Enzhao Jia; Lei Zhang; Yongsheng Han; Ronald Rodriguez; Tianjiang Ma
Journal:  Front Oncol       Date:  2021-04-20       Impact factor: 6.244

4.  Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.

Authors:  Yuriko Minegishi; Kazuma Kiyotani; Kensaku Nemoto; Yoshikage Inoue; Yoshimi Haga; Risa Fujii; Naomi Saichi; Satoshi Nagayama; Koji Ueda
Journal:  Commun Biol       Date:  2022-08-18

5.  Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.

Authors:  Chuan Zhang; Kun Ma; Wu-Yin Li
Journal:  Drug Des Devel Ther       Date:  2019-12-04       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.